Skip to main content
SpringerLink
Log in

B-Type Natriuretic Peptide: Physiologic Role and Assay Characteristics

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

The discovery of cardiac natriuretic peptides two decades ago has lead to considerable research to investigate their biochemical and physiological properties. Clearly the heart is not just a pump but is also an endocrine organ that together with the kidneys control volume overload. The natriuretic peptides are a group of structurally similar but genetically distinct peptides that exhibit diverse actions in cardiovascular, renal, and endocrine homeostasis. Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin. BNP is released mainly from the left ventricle in response to volume overload and has become the first biochemical marker for the identification of individuals with congestive heart failure (CHF). The development of assays, including rapid point-of-care tests, has made BNP measurement a clinical reality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Chapter © 2017

References

  1. Maisel A. B-type natriuretic peptide levels: A potential novel “white count” for congestive heart failure. J Cardiac Failure 2001;7:183–193.

    Google Scholar 

  2. Clerico A, Iervasi G, Mariani G. Clinical relevance of the measurement of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487–498.

    Google Scholar 

  3. Boomama F, Van der Meiracker AH. Plasma A-and B-type natriuretic peptides: Physiology, methodology and clinical use. Cardiovasc Res 2001;51:442–449.

    Google Scholar 

  4. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, Schocken DD. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994;90:1129–1140.

    Google Scholar 

  5. Schulz-Knappe P, Forssmann K, Herbst F, HockD, Pipkorn R, Forssmann WG. Isolation and structural analysis of “urodilatin”, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988;66:752–759.

    Google Scholar 

  6. Ambrose TM. Review of the clinical utility of NT-proBNP in the diagnosis, prognosis, and therapy monitoring of patients with congestive heart failure. J Clin Ligand Assay 2002;25:160–166.

    Google Scholar 

  7. De Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996;31:7–18.

    Google Scholar 

  8. Mair J, Hammerer-Lercher A, Puchendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571–588.

    Google Scholar 

  9. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195–203.

    Google Scholar 

  10. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett JC Jr. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684–H1689.

    Google Scholar 

  11. Selvais P, Donckier J, Robert A, et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: Influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest 1998;28:636–642.

    Google Scholar 

  12. Yamamota K, Burnett J, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988–994.

    Google Scholar 

  13. Clerico A, Iervasi G, Del Chicca M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170–179.

    Google Scholar 

  14. Janssen WM, de Zeeuw D, van der Hem GK, de Jong PE. Antihypertensive effect of a 5-day infusion of atrial natriuretic factor in humans. Hypertension 1989;13:640–646.

    Google Scholar 

  15. MukoyamaM, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402–1412.

    Google Scholar 

  16. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma Brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825–832.

    Google Scholar 

  17. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349–1353.

    Google Scholar 

  18. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci 1998;95:519–529.

    Google Scholar 

  19. Stein B, Levin R. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease. American Heart Journal 1998;135:914–923.

    Google Scholar 

  20. Weidmann P, Hasler L, GnadingerMP, Lang RE, Uehlinger DE, Shaw S, Rascher W, Reubi FC. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986;77:734–742.

    Google Scholar 

  21. Charles CJ, Espiner EA, Richards AM. Cardiovascular actions of ANF: Contributions of renal, neurohumoral, and hemodynamic factors in sheep. Am J Physiol 1993;264:R533–R538.

    Google Scholar 

  22. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996;81:3871–3876.

    Google Scholar 

  23. Davidson NC, Struthers AD. Brain natriuretic peptide. Journal of Hypertension 1994;12:329–336.

    Google Scholar 

  24. Clerico A, Iervasi G, Mariani G. Clinical relevance of the measurement of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487–498.

    Google Scholar 

  25. Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailly KR, Maisel A. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation. Am Heart J 2002;144:834–839.

    Google Scholar 

  26. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J AmColl Cardiol 2002;40:976–982.

    Google Scholar 

  27. Friesinger GC, Francis J. Promises and perils of managed care for older patients with cardiac disease. Cardiol Clin 1999;17:67–77.

    Google Scholar 

  28. Murdoch DR, Byrne J, Morton JJ, McDonagh TA, Robb SD, Clements S, Ford I, McMurray JJ, Dargie HJ. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice. Heart 1997;78:594–597.

    Google Scholar 

  29. Buckley MG, Marcus NJ, Yacoub MH, et al. Prolonged stability of brain natruretic peptide: Importance for noninvasive assessment of cardiac function in clinical practice. Clin Sci 1998;95:235–239.

    Google Scholar 

  30. Tsuji T, Imagawa K, Masuda H, Haraikawa M, Shibata K, Kono M, Inouye K, Uchida K. Stabilization of human brain natriuretic peptide in blood samples. Clin Chem 1994;40:672–673.

    Google Scholar 

  31. Sagnella GA. Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 2001;38:83–93.

    Google Scholar 

  32. Kono M, Yamauchi A, Tsuji T, et al. An Immunoradiometric assay for brain natriuretic peptide in human plasma. Jpn Soc Nucl Med Technol 1993;13:2–7.

    Google Scholar 

  33. BNP test for rapid quantification of B-type natriuretic peptide [package insert]. San Diego, Calif: Biosite Diagnostics; 2000.

  34. Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Fail 2001;7:21–29.

    Google Scholar 

  35. Del Ry S, Giannessi D, Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared. Clin Chem Lab Med 2001;39:446–450.

    Google Scholar 

  36. Vogeser M, Jacob K. B-type natriuretic peptide (BNP)— validation of an immediate response assay. Clin Lab 2001;47:29–33.

    Google Scholar 

  37. Baughman KL. B-type natriuretic peptide—a window to the heart. N Engl J Med 2002;347:158–159.

    Google Scholar 

  38. Kelly PM, Gaston S, Mackay R, Arthur K, Taylor V, Shih J, Matias M, Friese J, Weigand R. A novel assay for the measurement of plasma B-type Natriuretic Peptide by an AxSYM_R microparticle based immunoassay with use of stable liquid calibrators. Clin Chem 2002;48(suppl):A94, Abst # C-67.

    Google Scholar 

  39. Bluestein BI, Belenky A, Lin S, Despres N, Vajdi M, Armstrong G. Development of an automated test for Btype natriuretic peptide (BNP) as an aid in the diagnosis and evaluation of congestive heart failure on the Bayer ADVIA Centaur chemiluminescent system. Clin Chem 2002;48(suppl):A85, Abst # C-37.

    Google Scholar 

  40. Sokoll LJ, Baum H, Collinson P, Gurr E, Haass M, Luthe H, Morton I, Nowatzke W, Zingler C. Performance evaluation of Elecsys_R proBNP in amulticenter study. Clin Chem 2002;48(suppl):A91, Abst # C–56.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology and Medical & Research Technology, University of Maryland School of Medicine, Baltimore, USA

    Hassan M.E. Azzazy & Robert H. Christenson

Authors
  1. Hassan M.E. Azzazy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert H. Christenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert H. Christenson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azzazy, H.M., Christenson, R.H. B-Type Natriuretic Peptide: Physiologic Role and Assay Characteristics. Heart Fail Rev 8, 315–320 (2003). https://doi.org/10.1023/A:1026182912461

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026182912461

Search

Navigation